Research Analysts Set Expectations for IRWD Q2 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research dropped their Q2 2025 earnings estimates for Ironwood Pharmaceuticals in a report issued on Thursday, March 20th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.04. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.07 EPS, FY2026 earnings at $0.24 EPS and FY2027 earnings at $0.36 EPS.

Several other analysts also recently issued reports on the stock. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. JMP Securities reduced their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Finally, Craig Hallum decreased their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.60.

Ironwood Pharmaceuticals Stock Up 0.7 %

NASDAQ IRWD opened at $1.50 on Monday. Ironwood Pharmaceuticals has a 52 week low of $1.34 and a 52 week high of $9.01. The business has a 50 day moving average price of $2.18 and a 200-day moving average price of $3.43. The company has a market cap of $240.04 million, a price-to-earnings ratio of -50.00 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV raised its stake in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in Ironwood Pharmaceuticals by 150.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company’s stock worth $520,000 after acquiring an additional 75,917 shares during the period. Intech Investment Management LLC purchased a new position in Ironwood Pharmaceuticals in the third quarter valued at about $181,000. Charles Schwab Investment Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company’s stock valued at $7,846,000 after acquiring an additional 364,841 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of Ironwood Pharmaceuticals by 21.2% during the 3rd quarter. Daiwa Securities Group Inc. now owns 67,570 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 11,800 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares in the company, valued at $2,042,715.84. The trade was a 10.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now directly owns 554,007 shares of the company’s stock, valued at $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 192,381 shares of company stock valued at $338,591 in the last three months. 12.90% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.